Ionis Pharmaceuticals, Inc. - Common Stock - Nakit Akışı (NASDAQ:IONS)

Financials

İşletme faaliyetlerinden elde edilen nakit 35.89 M30.8 M-274.37 M-307.51 M-500.95 M-268.58 M -910.63 M Yatırım faaliyetlerinden elde edilen nakit 274.48 M194.91 M-262.64 M-214.13 M-134.03 M-277.78 M 88.58 M Finansman faaliyetlerinden elde edilen nakit -596.61 M245.93 M-55.3 M644.08 M478.06 M675.84 M 730.9 M Serbest nakit akışı 35.89 M30.8 M-274.37 M-307.51 M-500.95 M-325.67 M -977.73 M

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

IONS

Financials

Ionis Pharmaceuticals, Inc. - Common Stock

Haberler

Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach (NASDAQ:IONS)

Wolfe Research rakip veri öncesi Ionis hisse notunu korudu

BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal

Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.

Stock Market Today: Nasdaq Charges Higher; Hot Nvidia Rival Surges On Debut (Live Coverage)

Biogen, Alzheimer ilacı diranersen için kayıt çalışması planlıyor

Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%

Oppenheimer, Ionis Pharmaceuticals için hedef fiyatı yükseltti